Telix Therapeutics
We are developing a new generation of cancer therapies that combine molecular precision with therapeutic radiation. Our therapeutic candidates are designed to locate and destroy cancer cells with high specificity, while preserving healthy tissue.
Our innovative pipeline targets urologic and neurologic cancers and other tumors, focusing on areas of significant unmet need to improve outcomes and reduce patient burden.
A unique therapeutic modality
Radiopharmaceuticals are a novel cancer treatment that combine a targeting agent that seeks out specific cancer cell markers.
Once bound to cancer cells, the isotope delivers targeted radiation that damages DNA, preventing cell growth and replication while minimizing impact on healthy tissue.
Where we’re making an impact
We focus on developing therapies for cancers with limited treatment options or where targeted radiation has the potential to improve outcomes. Our approach targets proteins uniquely expressed on cancer cells or within the tumor microenvironment, allowing for more precise delivery of therapy.
-
Prostate cancer
Prostate cancer is the most common cancer affecting men globally and a major cause of cancer-related mortality. Our therapies are designed to target PSMA (prostate-specific membrane antigen), which is abundantly expressed on prostate cancer cells but largely absent from healthy tissue — enabling more precise treatment.
Learn more -
Kidney cancer
Kidney cancer is a significant global health burden, with clear cell renal cell carcinoma (ccRCC) the most common and among the most aggressive subtypes. Our therapeutic candidate targets carbonic anhydrase IX (CAIX), a cell surface protein overexpressed in ccRCC and broadly expressed in a range of solid tumors.
Learn more -
Brain cancer
Primary brain tumors remain among the most challenging and deadly cancers, with limited treatment options. Our glioblastoma therapeutic candidates target LAT1, a validated protein highly expressed in many solid tumors, including those of the central nervous system. Targeting LAT1 enables these therapies to cross the blood-brain barrier and reach tumors in the brain, typically inaccessible to conventional therapies.
Learn more -
Blood cancer
Bone marrow conditioning (BMC) is a critical preparatory step before stem cell transplantation, particularly for patients with blood cancers such as acute myeloid leukemia and pediatric leukemia. Current BMC methods including with chemotherapy can be highly toxic, which many patients are unable to tolerate. Our BMC candidate targets cluster of differentiation 66 (CD66), a target expressed on specific immune/blood cells, to enable precise delivery of radiation to the bone marrow, supporting conditioning before stem cell transplant while minimizing damage to healthy tissue.
Learn more -
Pan-cancer
Our pan-cancer programs target CAIX and fibroblast activation protein (FAP), two well-validated targets with pan-cancer potential. By targeting CAIX and FAP, we are aiming to deliver radiation directly into the tumor microenvironment, offering a new approach for hard-to-treat cancers, including solid tumors which may be resistant to conventional therapies.
Learn more -
Musculoskeletal cancers
Musculoskeletal cancers, including sarcomas and bone cancers, present significant treatment challenges. Our therapeutic candidate for soft tissue sarcoma, TLX300-Tx, targets platelet-derived growth factor receptor alpha (PDGFRα), a protein expressed on the surface of multiple tumor types.
Learn more -
Bone pain
We are also developing TLX090-Tx, a bone-targeting therapeutic candidate for metastatic bone pain, aiming to provide a more precise and durable approach to pain management in patients with advanced cancer, including prostate and breast cancer that has spread to the skeleton.
Learn more
Prostate cancer is the most common cancer affecting men globally and a major cause of cancer-related mortality. Our therapies are designed to target PSMA (prostate-specific membrane antigen), which is abundantly expressed on prostate cancer cells but largely absent from healthy tissue — enabling more precise treatment.
Learn more
Kidney cancer is a significant global health burden, with clear cell renal cell carcinoma (ccRCC) the most common and among the most aggressive subtypes. Our therapeutic candidate targets carbonic anhydrase IX (CAIX), a cell surface protein overexpressed in ccRCC and broadly expressed in a range of solid tumors.
Learn more
Primary brain tumors remain among the most challenging and deadly cancers, with limited treatment options. Our glioblastoma therapeutic candidates target LAT1, a validated protein highly expressed in many solid tumors, including those of the central nervous system. Targeting LAT1 enables these therapies to cross the blood-brain barrier and reach tumors in the brain, typically inaccessible to conventional therapies.
Learn more
Bone marrow conditioning (BMC) is a critical preparatory step before stem cell transplantation, particularly for patients with blood cancers such as acute myeloid leukemia and pediatric leukemia. Current BMC methods including with chemotherapy can be highly toxic, which many patients are unable to tolerate. Our BMC candidate targets cluster of differentiation 66 (CD66), a target expressed on specific immune/blood cells, to enable precise delivery of radiation to the bone marrow, supporting conditioning before stem cell transplant while minimizing damage to healthy tissue.
Learn more
Our pan-cancer programs target CAIX and fibroblast activation protein (FAP), two well-validated targets with pan-cancer potential. By targeting CAIX and FAP, we are aiming to deliver radiation directly into the tumor microenvironment, offering a new approach for hard-to-treat cancers, including solid tumors which may be resistant to conventional therapies.
Learn more
Musculoskeletal cancers, including sarcomas and bone cancers, present significant treatment challenges. Our therapeutic candidate for soft tissue sarcoma, TLX300-Tx, targets platelet-derived growth factor receptor alpha (PDGFRα), a protein expressed on the surface of multiple tumor types.
Learn more
We are also developing TLX090-Tx, a bone-targeting therapeutic candidate for metastatic bone pain, aiming to provide a more precise and durable approach to pain management in patients with advanced cancer, including prostate and breast cancer that has spread to the skeleton.
Learn moreExplore clinical trials
Telix’s therapeutic candidates are studied in partnership with leading global cancer centers.
Therapeutic pipeline
FOOTNOTES
- PSMA – prostate-specific membrane antigen
- mCRPC – metastatic castration-resistant prostate cancer
- mHSPC – Metastatic hormone-sensitive prostate cancer
- CAIX – carbonic anhydrase IX
- ccRCC – clear cell renal cell carcinoma
- Bone mets – bone metastases
- LAT1 – L-type amino acid transporter 1
- GBM – glioblastoma multiforme
- LMD – leptomeningeal disease
- CD66 – cluster of differentiation 66
- AML – acute myeloid leukaemia
- FAP – fibroblast activation protein
- PDGFRα – platelet-derived growth factor receptor alpha
- STS – soft tissue sarcoma